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Abstract
Background: Worldwide, cervical cancer is the second most common cancer in women. High-risk human
papillomavirus (HPV) play a crucial role in the etiology of cervical cancer and the most prevalent genotype is
HPV16. HPV 16 intratypic variants have been reported to differ in their prevalence, biological and biochemical
properties. The present study was designed to analyze and identify HPV type 16 E6 variants among patients with
cervical cancer in Morocco.
Methods: A total of 103 HPV16 positive samples were isolated from 129 cervical cancer cases, and variant status
was subsequently determined by DNA sequencing of the E6 gene.
Results: Isolates from patients were grouped into the European (E), African (Af) and North-American (NA1)
phylogenetic clusters with a high prevalence of E lineage (58.3%). The Af and NA1 variants were detected in 31.1%
and 11.6% of the HPV16 positive specimens, respectively, whereas, only 3% of cases were prototype E350T. No
European-Asian (EA), Asian (As) or Asian-American (AA) variants were observed in our HPV16-positive specimens.
At the amino acid level, the most prevalent non-synonymous variants were L83V (T350G), H78Y (C335T), E113D
(A442C), Q14D (C143G/G145T) and R10I (G132T), and were observed respectively in 65%, 41.8%, 38.8%, 30.1% and
23.3% of total samples.
Moreover, HPV16 European variants were mostly identified in younger women at early clinical diagnosis stages.
Whereas, HPV16 Af variants were most likely associated with cervical cancer development in older women with
pronounced aggressiveness.
Conclusion: This study suggests a predominance of E lineage strains among Moroccan HPV 16 isolates and raises
the possibility that HPV16 variants have a preferential role in progression to malignancy and could be associated
with the more aggressive nature of cervical cancer.
Keywords: Cervical cancer, Human papillomavirus 16, Variants, E6, Morocco
Background
Cervical cancer is the second most predominant cancer
worldwide, and more than 85% of the global burden oc-
curs in developing countries, where it accounts for 13%
of all female cancer [1]. In Morocco, as it is the case in
the other North African countries, cervical cancer is the
second most common cancer among women and its inci-
dence is the highest in this region with an age-
standardized incidence rate (ASR) of 13.5 per 100 000
women [2]. Persistent infection with high risk Human
papillomavirus (HPV) is the main aetiological factor in the
development of cervical cancer. Globally, HPV16 is the
most frequent HPV type found in cervical cancer and is
identified in approximately 65% of cases [3]. In Morocco,
our previous reports have shown that the HPV16 is also
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Given that the prevalence of cervical cancer varies in
different regions and countries, a number of studies have
addressed the possible association of HPV16 variant sta-
tus with the risk for progression to malignancy. HPV
variants are defined as isolates with primary DNA se-
quence differences that total no more than 2% of the L1
open reading frame (ORF) of the prototype sequence
[7]. The sequence variations of the HPV16E6 ORF have
been found to correctly classify the HPV16-variants [8].
Therefore, most studies on HPV16 variants have focused
on E6, the major transforming protein that inhibit apop-
tosis and promote proliferation and their association to
cancer aggressiveness [9-11]. Worldwide, variants of the
HPV16 genome in cervical carcinoma, precancerous le-
sions and normal or inflammatory cervical cases, from
different geographical areas have been classified into
phylogenetic lineages as European (E), Asian (As),
Asian-American (AA), African -1 and -2 (Af1 and Af2),
and North American1 (NA1) [8,12,13]. Overall, multiple
studies have shown that HPV16 variants differ in risk for
progression to high grade intraepithelial lesions [14-16],
in their association with the development of cervical
cancer [15,17-19], viral persistence [17,20-26] and the
frequency of recurrence of cervical disease [15].
Many authors confirm that distribution of HPV vari-
ants is related to geographic or race distribution [27].
However, although numerous studies on HPV16 variants
in cervical cancer have been carried out so far world-
wide, only one HPV variant research in patients from
Tunisia has been performed in North Africa [28]. To
our knowledge, nothing is known concerning HPV vari-
ants in patients from Morocco, where there is a signifi-
cantly high occurrence of this tumor. In the present
study entirely done in Morocco, we have examined
whether naturally occurring sequence variations in the
HPV16 E6 gene exist in cervical cancer from Moroccan
subjects with HPV 16 infection. The identification of
more persistent or oncogenic HPV16 variants would be
of great interest in the global strategy in the develop-
ment and implementation of improved therapeutic vac-
cines against HPV.
Furthermore, HPV sequence variations studies can be
used in epidemiological studies as a marker to track the




One hundred twenty nine fresh frozen uterine cervix bi-
opsies were recruited for the variant analysis in the
present study. The tumor samples were from biopsies
collected for the routine diagnosis of cervical cancer
from Gynaecology department of the National Institute
of Oncology in Rabat and Oncology Centre Mohammed
VI pour le Traitement des Cancers, CHU Ibn Rochd in
Casablanca, that receive patients from all regions of
Morocco. The mean age of patients was 52 ± 12 years,
with extreme ages at 28 and 80. Each sample was di-
vided into two portions: one portion was put in neutral
buffered formalin and processed for routine histopatho-
logical examination; the other portion was stored at
−80°C immediately after surgical removal, for HPV
genotyping. Protocols were approved by Ethical Review
Committees of the Faculty of Medicine of Fez and the
Hassan-II University Hospital, and written informed
consent was obtained from each study subject.
Cell lines
CaSki and SiHa cervical cancer cell lines were obtained
from the American Type Culture Collection (ATCC)
and used as positive controls. These cell lines were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS).
Pathology
Samples were fixed in 10% buffered-formaldehyde. Path-
ology diagnosis was made using the routine hematoxylin-
eosin stain on 5 μm paraffin sections. Histopathological
results of cervical cancer lesions were classified according
to the International Federation of Gynaecology and Ob-
stetrics (FIGO).
DNA extraction
Genomic DNA was extracted from fresh frozen tissue and
cervical cancer cell lines using a standard technique of di-
gestion with proteinase K in the presence of sodium
dodecyl sulfate (SDS) at 37°C overnight, followed by phe-
nol/chloroform purification [29]. The tissue DNA was pre-
cipitated with 2/5 volumes of 7.4 M ammonium acetate
and 2 volumes of 100% ethanol, followed by incubation
at −20°C and centrifugation at top speed (13000 relative
centrifugal force). DNA was then resuspended in 25–
30 μL of sterile distilled water and stored at −20°C until
use. In order to evaluate the efficiency of DNA extraction,
all samples were amplified by PCR using PC04 and GH20
primers specific for human β-globin gene (Table 1).
HPV genotyping
HPV detection and genotyping of cervical cancer cases
were performed using a nested PCR, with the consensus
MY09/11 and GP5+/6+ primers (Table 1), and direct
DNA sequencing [30]. All specimens were first subjected
to PCR amplification with HPV consensus primers
MY09/11 [31]. For nested PCR, 2 μL of the MY09/11
PCR products was used as a template for PCR amplifica-
tion using GP5+/6+ general primers [30,32]. For every
reaction, a negative control, in which DNA template was
omitted from the amplification mixture, and a positive
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control, with DNA extracted from SiHa and Caski cell
lines, were included. PCR products were analyzed by
electrophoresis on 2% agarose gels followed by staining
with ethidium bromide (10 mg/mL).
For DNA sequencing, the PCR products were purified
by the ExoSaP-IT clean up system (USB, USA) and se-
quenced directly on an ABI 3130XL DNA analyzer (Ap-
plied Biosystems, Foster city, CA, USA), using GP6+
primer as the sequencing primer and BigDye® Terminator
v3.1 Cycle Sequencing Kit (AppliedBiosystems, Foster city,
CA, USA), according to manufacturer’s protocol. For each
sample, PCR amplification and DNA sequencing were
performed twice. Nucleotides sequences were aligned and
compared with those of known HPV types available
through GenBank by using the online BLAST 2.0 software
server (http://www.ncbi.nih.gov/blast). In accordance with
established guidelines, a nucleotide sequence was assigned
to an HPV type if it corresponded with a known HPV
genotype by >90% [33].
Determination of HPV16 E6 variants
Samples with a single HPV16 genotype were selected for
E6 variants investigation. Determination of HPV16 E6 var-
iants was performed by E6 specific PCR, using primers
flanking the encoding region of HPV16 E6 gene (nt 52–
575) (Table 1), and DNA sequencing.
PCR amplifications were performed according to Lizano
et al. [34]. For every reaction, positive controls using DNA
extracted from SiHa and Caski cell lines, as well as a nega-
tive control without template DNA, were included. PCR
products were tested on an ethidium bromide stained 2%
agarose gel. PCR products were purified and sequenced
with the same primers as those used for the amplifi-
cation [34]. The HPV16 E6 sequences obtained were
aligned with those of European prototypes of HPV16 se-
quence (HPV16-R) (GenBank accession numbers: K02718,
NC_001526), available through the GenBank database
(NCBI, National Institute of health, Bethesda, MD, USA),
using the BLAST 2.0 software server (http://www.ncbi.nih.
gov/BLAST/), MEGA v4.0 and SeqScape v2.6 (Applied
Biosystems, Foster city, USA) programs.
Statistical analysis
The HPV16 variants according to other clinical features
were compared using a Fisher’s exact test using the
MedCalc statistical software (http://www.medcalc.org).
The statistical relationship was considered as significant
if the derived p value was < 0.05.
Results
Histopathological data
The pathological analysis revealed the predominance of
Squamous Cell Carcinoma (SCC) that represents 96.89%
of cases (125/129). The remaining 4 cases (3.1%) were di-
agnosed as adenocarcinoma. According to stage, to the
most important percentages were found in stage II and III
representing 48.8% (61 cases) and 38.4% (48 cases), re-
spectively. Moreover, 14 cases were classified as stage I
(11.2%), whereas only 2 cases (1.6%) were classified as
stage IV.
Subtype distribution of HPV DNA
The presence of amplifiable DNA was confirmed for all
129 cases by PCR based-technique using primers for a
fragment of β-globin gene and therefore all DNA sam-
ples were adequate for further analysis. Molecular detec-
tion of HPV DNA, using nested PCR amplification of a
conserved region of the HPV L1 gene DNA with the
consensus MY09/11 and GP5+/6+primers, revealed the
presence of viral DNA in 91.47% (115 of 129 SCC and 3
of 4 adenocarcinoma).
In this study, we have identified 5 carcinogenic HPV
genotypes: 16, 18, 31, 33 and 35. The most frequently
found was HPV16, detected in 87.29% of all positive
samples (103 cases), followed by HPV 18, present in
5.08% of samples (6 cases), HPV 31 in 2.54% of samples
(3 cases), HPV 33 in 1.69% of samples (2 cases) and
HPV 35 in 1 specimen (0.85% of cases). Undetermined
HPV genotypes were identified in 3SCC cases.
Sequence variations of HPV16 E6 gene
The 103 HPV16 single infected specimens were se-
lected for E6 intratypic variation analysis. Overall, DNA
Table 1 List of primers used for PCR amplification and DNA sequencing
Primer Fragment generated size Sequence Tm (°C)
β-globin PC04 268 bp 5′-CAACTTCATCCACGTTCACC-3′ 54.5
GH20 5′-GAAGAGCCAAGGACAGGTAC-3′
HPV detection & genotyping MY09 450 bp 5′-CGT CCM ARR GGA WAC TGATC- 3′ 55
MY11 5′-GCM CAG GGW CAT AAY AAT GG-3′
GP5+ 150 pb 5′-TTTGTTACTGTGGTAGATACTAC-3′ 55
GP6+ 5′-CTTATACTAAATGTCAAATAAAAA-3′
HPV16 E6 variants F 524 bp 5′-CGAAACCGGTTAGTATAA-3′ 55
R 5′-GTATCTCCATGCATGATT-3′
F: Forward primer; R: Reverse primer
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sequences were compared to the HPV16 reference se-
quence (Accession Number: K02718, NC_001526). Ac-
cordingly, HPV16-positive specimens were classified
into E, Af1, Af2 and NA branches (Table 2).
By comparison with the prototype sequence of HPV16
E6, it was found that only 2.9% of samples (3 out 103)
revealed the prototype sequence, while 97.1% of samples
(100 out 103) showed at least one specific nucleotide
variation in the HPV16 E6 region (Table 2). Moreover,
in all analyzed specimens, there was no evidence of pre-
mature stop codons, bases insertions or deletions.
Overall, 9 variants with predicted E6 amino acid
changes were identified (Table 2). The most prevalent
non-synonymous variants were L83V (T350G), H78Y
(C335T), E113D (A442C) and Q14D (C143G/G145T)
and were observed respectively in 65%, 41.8%, 38.8% and
30.1% of total samples. The other non-synonymous vari-
ants were R10I (G132T), R10G (A131G), D64E (T295G),
Q14H (G145T) and A61G (C285G) and were seen in
23.3%, 6.8%, 6.8%, 1.9% and 1% of cases respectively.
A total of 12 different intratypic variants were identi-
fied among the 103 HPV16 specimens isolated from
Moroccan women. These intratypic variants are grouped
into three different variant classes, including European
(E), African (Af) and the North-American (NA1) variant
classes. The European variants HPV16 were the most
frequently detected isolates in our population and repre-
sent 58.3% of total HPV16 isolates (n=60), followed by
Af characterized in 30.1% of cases (n=31). Whereas the
NA variants were found only in 11.6% of cases (n=12)
(Table 2). In the European class, two sub-classes prevail,
E-350G/442C identified in 40 specimens (38.8%) and E-
350G identified in 16 specimens (15.5%). The common
no-E variants are represented by Af2, NA1 and Af1 sub-
classes, which are identified in 24 (23.3%), 12 (11.6%)
and 7 (6.8%) cases, respectively. Asian (As) and Asian-
American (AA) HPV16 variants were not detected in
the present study.
The distribution of the different E6 variations in the
HPV16 positive samples with respect to FIGO staging of
cervical neoplasia is reported in Table 3. E class variants,
the most common intratypes, were mainly associated
with cancers detected in early clinical stages. The major-
ity of cervical neoplasia with HPV16 E variant lesions
presented at stage I and II with 75% (9/12) and 60% (30/
50) respectively. Conversely, Af variants seem to be most
likely detected in advanced cancer stages, there were
detected in 37.5% (15/40) of cases at stage III and only
in 16.67% (2/12) and 28% (14/50) of cases at stages I
and II respectively. NA1 variants were detected with
similar frequencies in early as well as advanced stages.
However, no significant statistical difference between
HPV variant and stage (early I and II, advanced III and
IV) of cancer was detected (p > 0.05).
The distribution of HPV16 E6 variants according to
patients’ age was also assessed and is reported in Table 4.
Results showed an overrepresentation of Af class in the
age group over 45 years old whereas E and NA variants
were most identified in the age group under 45 years.
Moreover, among women under 45 years, E350G/442C
is the most predominant variant with 48.15% of cases
(13/27). However, in women over 45 years, two variants
prevail: E350G/442C and Af2 which are present in
35.53% (27/76) and 25% (19/76) respectively, statistical
analyses were significant for only HPV16 E and Af vari-
ants related to patients’ age (p < 0.0001).
Correlation between HPV16 E6 variants and malignant
phenotype showed that E variants are mostly associated
with high degree of differentiation, moderately and well
differentiated carcinoma, whereas Af variants are more fre-
quently found in poorly differentiated carcinoma (Table 5).
Discussion
The present study, entirely realized in Morocco, highlighted
the distribution patterns of intratypic variants of HPV16
among women with cervical cancer. A total of 129 samples
of cervical cancer cases were collected. Molecular detection
of HPV, using nested PCR amplification of a conserved re-
gion of the HPV L1 gene with the consensus MY09/11 and
GP5+/6+ primers, revealed the presence of viral DNA in
91.47% of cases (118/129). We identified 5 carcinogenic
HPV genotypes (16, 18, 31, 33 and 35). Globally, HPV
prevalence and distribution is in concordance with previ-
ously reported data in Morocco [4,6], and tally with the
overall world distribution of HPV types in cervical cancer
[36,37]. Moreover, HPV16 was the HPV genotype most fre-
quently found in our study population, with 87.29% of all
positive samples, which is in agreement with the worldwide
reported data [3,18,37,38]. However, previous studies
conducted in Morocco have reported lower prevalence of
HPV16.
Lalaoui et al. [4] have found HPV 16 in 49% of HPV
positive cases, whereas in the study of Meftah El Khair
et al. [31], HPV16 was found in 71% of HPV positive
cases, including mono-infected (37%) and co-infected
(34%) cases. This difference may be related to the sam-
pling bias but also could be due to the molecular tech-
nique used for the HPV genotyping. In the previous
studies, HPV genotyping was realized by combining con-
sensus PCR and dot blot hybridization with specific
probes. However, in our study, the HPV genotyping was
performed by DNA sequencing of the hyper-variable re-
gion in L1 fragment which is reported to be more accur-
ate and give a high sensitivity [30,33].
To examine the prevalence of naturally occurring se-
quence variations in the HPV16 E6 gene in cervical can-
cer from Moroccan subjects, all HPV16 positive samples
(n=103) were subjected to intratypic variant analysis by
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Table 2 Characterization of HPV16 E6 variants and their lineage classification
HPV 16 variants N T109C A131G G132T C143G G145T C285G T286A A289G T295G T325C C335T T350G A403G A442C Predicted substitution
HPV16 Reference T A G C G C T A T T C T A A
Lineage Sub-lineage Class/sub-class
EUR Ep E-T350 3 - - - - - - - - - - - - - -
E-350G E-G350 16 - - - - - - - - - - - G - - L83V
E-C442/G350 40 - - - - - - - - - - - G - C L83V/E113D
E-G350/T145 1 - - - - T - - - - - - G - - Q14H/L83V
AFR Af1 Af1-d/G295 5 - G - G T - a g G - T G - R10G/Q14D/D64E/
H78Y/L83V
Af1-d/G295/C325 2 - G - G T - a g G c T G - - R10G/Q14D/D64E/
H78Y/L83V
Af2 Af2-a/C109/G403 13 c - T G T - a g - - T - g - R10I/Q14D/H78Y
Af2-a/G285 1 - - T G T G a g - - T - g - R10I/Q14D/A61G/H78Y
Af2a/r 10 - - T G T - a g - - T - g - R10I/Q14D/H78Y
NA NA1 NA1 9 - - - - - - a g - - T - g - H78Y
NA1 2 - - - - - - a g - - T G - - H78Y/L83V
NA1-b/r 1 - - - - T - a g - - T G - - Q14D/H78Y/L83V
N* 13 7 24 31 33 1 43 43 7 2 43 67 33 40
Sequence alterations relative to the E6 open reading frame (ORF) of the reference HPV16 sequence [35]. For subclasses, the number and the letter represent the nucleotide change at that position. Lower case
represents a nucleotide change at that position without an amino acid change. Capital letters indicate variants with an amino acid change. In the ‘Predicted substitution’ column, the letter preceding the amino acid






















nucleotide sequencing of the E6 gene and comparison
with the prototype sequence of HPV16 E6.
Of all HPV16 positive samples, only 3 cases exhibited
a prototype E6 gene sequence and 97.1% of cases (100/
103) showed at least one specific nucleotide variation in
the HPV16 E6 region. This finding is in agreement with
published results reporting that approximately 90% of
the E6 genes in invasive cervical cancer contained varia-
tions [39,40].
It is widely accepted that the distribution of HPV vari-
ants is related to geographic or race distribution [21,27]
and therefore, owing to the geographic location of
Morocco in the North Africa, we expected the predom-
inance of African variants. Unexpectedly, however, the
E6 gene sequencing analyses highlighted that the most
frequently HPV16 variants detected in our population
belonged to the European lineage (58.3%), whereas the
African lineage was detected only in 30.1% of cases. The
NA1 lineage was less represented and limited to 11.6%
of cases. The frequent circulation of the European
lineage in Morocco most likely reflects the immigration
flow that characterized this region for a long time in the
past. Morocco, due to its geographic position, is recog-
nized as a border region between Europe and Africa,
and therefore was a corner stone in all exchanges be-
tween the two continents. Authors have already reported
that HPV strains could be introduced as a result of migra-
tion leading to the spread of the molecular variants of
HPV from one continent to another [41]. Krennhrubec
et al. [28] have reported the same results in Tunisia, a
neighbor country in North Africa, with 64% of HPV16 in-
fections being of European lineage.
HPV16 European variant is a highly spread variant
around the world, a meta-analysis conducted on HPV16
positive tumors samples collected globally from different
ethnical group reported that European lineage was the
most predominant lineage and was well distributed
among the different geographical regions. This wide-
spread presence suggests biological relevance of this
variant [42].
A large number of HPV16 variants circulating in our
population belong to African branches (30.1% of cases).
The association of Af variants with an increased risk of
cervical cancer development is controversial. Some au-
thors have reported a greater association between infec-
tion with HPV16 Af variants and an increased risk of
cervical carcinogenesis [15,43,44]. However, Tu et al.
[45] have reported no evidence that Af variants could be
associated with an increased risk of neoplasia. Within
the Af lineage, the two main subgroups, Af1 and Af2
were detected in 7 (6.8%) and 24 (23.3%) cases respect-
ively. These results are in contrast to previous studies
Table 3 Distribution of HPV16 E6 variants according to clinical stage
Clinical
stage
N E Af NA
E350G E350G/442C E-G350/G145 Ep Af1 Af2 NA1
I 12 2 7 - - 1 1 1
9 2
II 50 10 18 1 1 2 12 6
30 14
III 40 4 14 - 2 4 11 5
20 15
IV 1 - 1 - - - - -
1
Subtotal 16 40 1 3 7 24 12
Total 103 60 31 12
Table 4 Distribution of HPV16 E6 variants according to patients’ age
Patients’ age N E Af NA
E350G E350G/442C E-G350/G145 Ep Af1 Af2 NA1
≤ 45 years 27 4 13 - - - 5 5
17 5 5
> 45 years 76 12 27 1 3 7 19 7
43 26 7
Subtotal 16 40 1 3 7 24 12
Total 103 60 31 12
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that reported the predominance of Af1 variants, among
the Af lineage, in North Africa [12,42].
Interestingly, we have detected NA1 lineage in 11.6% of
our patients’ population. The occurrence of NA1 classes,
which is a derivative of the AA and Af2 variants [12], is
difficult to explain. The NA1 lineage, identified in 1990s
[12], was recently found to be particularly frequent in
samples from North Africa [42]. We believe that NA1
lineage could be introduced recently in Morocco and
spread in the population. That could explain the lower fre-
quency of this lineage in the study population.
According to clinico-pathological data, HPV16 European
variants (350G alone or along with other mutations)
were mostly identified in younger women at early
clinical stages (I and II) at diagnosis. However, most of
the cancer patients, harboring the HPV16 Af variants,
were older (over 45 years) and exhibited a pronounced
aggressiveness of the disease, as the majority of cases
were at advanced stage (III) with poorly differentiated
carcinoma. These results raise the possibility that
HPV16 variants have a preferential role in progression
to malignancy and could be associated with the more
aggressive nature of cervical cancer. Similar results
were obtained in Tunisia reporting a higher proportion
of non-European HPV16 variants in advanced stage
(III). In contrast, the non-E variants were more fre-
quently detected at earlier average age at diagnosis than
European variants [28]. This difference could not be
due to genetic diversity of the host, as the two popula-
tions are very closely related, but could be due to a
sampling bias and biological behavior of the host.
Most nucleotide changes reported in our study have
been previously described and some of them are of par-
ticular interest and may have considerable biological
impact [10,46]. The most prevalent non-synonymous
variants were L83V (T350G), H78Y (C335T), E113D
(A442C), Q14D (C143G/G145T) and R10I (G132T), and
were observed respectively in 65%, 41.8%, 37.9%, 30.1%
and 23.3%of total samples. Against the above back-
ground of higher pathogenicity associated with the L83V
variant, the finding of our study reiterates the same. In-
deed, the most frequently observed mutation in our study
was L83V which is detected in 65% of cases (67/103),
either alone (15.5% of cases) or along with other muta-
tions (49.5% of cases). This mutation is the most com-
monly found in HPV16 E6 gene from cervical invasive
cancers [44], and has been linked to an increased risk for
cervical disease progression [20]. Many authors addressed
a geographic variation of the oncogenicity of this variant
[22,39,47]. In some European populations, HPV16 E350G
variant was strongly associated with the oncogenicity
and persistency of HPV16 infection [20,39]. Moreover,
HPV16 E350G variant was found to display more effi-
cient degradation of Bax (protein regulated by p53)
and binding to E6-BP (E6 binding protein) and de-
creased binding to human discs large protein (hDlg)
[48]. This variant appears to have surpassed the E6
prototype in enhancing the mitogen activated protein
kinase (MAPK) signaling evolved in oncogenic ras-
mediated transformation and in the cooperative trans-
formation with the deregulated Notch 1 pathway [49].
Also, this L83V polymorphism appears to interact with
natural human variations in the p53 genes (in particu-
lar codon 72 polymorphism) to confer differences in
cervical cancer risk [50].
Additionally, E6 variants R10G/L83V and Q14H/
H78Y/L83V which are frequently detected in our study,
were more prone to undergo cell-detachment-induced
apoptosis than E6 prototype in a model of human nor-
mal immortalized keratinocytes (NIKS) [51] and has a
greater in vitro ability to suppress keratinocyte differen-
tiation responses and to induce p53 degradation than
the prototype [52].
Interestingly, the E113D (A442C) was detected in
37.9% of samples and was exclusively found in the
European variant (E350G/442C). This point mutation is
Table 5 Correlation between malignant phenotype and HPV16 E6 variants
Differentiation N E Af NA
E350G E350G/442C E-G350/G145 Ep Af1 Af2 NA1
Poorly 17 3 4 - - 1 7 2
7 8
Moderately 39 5 18 1 2 4 7 2
26 11
Well 31 6 13 - - 1 6 5
19 7
Unknown 16 2 5 - 1 1 4 3
8 5
Subtotal 16 40 1 3 7 24 12
Total 103 60 31 12
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largely reported in Asian populations and is implied in
invasive cervical carcinoma [53-55].
The majorities of the E6 amino acid switches in our
samples were located at amino acid residues10, 14, 78
and 83 and were shown to be under positive selective
pressure [56,57]. This selection pressure, driven by pro-
tein–protein polymorphic interactions, could facilitate
the life cycle and pathogenicity of HPV associated dis-
ease and might be under immune selection [57]. Most
recently, Bayesian analysis identified several important
amino acid positions that may be driving adaptive selec-
tion in the HPV 16 population, including R10G, L83V,
and E113D in the E6 gene [48]. Therefore, the positive
selection at these codons might be a contributing factor
responsible for the phenotypic differences in carcinogen-
esis and immunogenicity among cervical cancers in
Morocco. Indeed, it has been suggested that women
with three distinct HLA class I alleles, namely HLA-
B*44, HLA-B*51, or HLA-B*57 who were infected with
the HPV16 E6 variant L83V had an approximately four
to five fold increased risk for cancer compared with con-
trols [49,58]. Additionally, in another study, the HPV 16
E6 variant G131 (R10G) was demonstrated to alter a
B*07 binding epitope such that it may influence immune
recognition by cytotoxic T lymphocytes [59]. Also, the im-
munologic relevance of the HPV16 E6 N-terminal region
and variant positions E6 amino acids 10 and 14 is sup-
ported by the demonstration of an endogenously processed
HLA A*0201-restricted E6 peptide (E6 amino acids 11 to
19) as well as of an overlapping HLA B-7-restricted E6 pep-
tide (E6 amino acids 8 to 15) in this region [59,60].
Therefore, the observed amino acid variations in
HPV16 E6 detected in our study may impact on the viral
life cycle, which is tightly linked to the differentiation
program of the cell [57].
Conclusion
The introduction of molecular sub-typing of HPV allowed
better genotyping and therefore a better characterization
of strains circulating in Morocco. Thereby, the identifica-
tion of HPV16 E, Af and NA1 variants suggests a different
sexual mixing behavior. Their circulation in our popula-
tion may involve a change in the biological properties and
a change in the transforming potential, increasing the risk
of cervical cancer development. Currently, Morocco is a
destination of many sub-Saharan migrants looking for
better life, and is also a gateway to Europe, that war-
rants the need for monitoring a wider range of HPV var-
iants involved in cervical cancer in Morocco. Thus, in
order to better understand the dynamics of the disease
and to optimize current control programs and policies
for a better survey of cervical cancer, it is useful to de-
velop routine epidemiological surveillance, including
molecular sub-typing.
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